Global pharmaceutical company Merck (NYSE: MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year on year to $16.29 billion. The company expects the full year’s revenue to be around $66.4 billion, close to analysts’ estimates. Its non-GAAP loss of $1.28 per share was 13.2% above analysts’ consensus estimates.

Is now the time to buy MRK? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as meaningful contributions from recent product launches. Management highlighted the continued growth of KEYTRUDA, particularly in metastatic and earlier-stage cancers, and emphasized rising demand for WINREVAIR and WELIREG within the broader oncology portfolio. The company also pointed to key regulatory and product milestones, such as the FDA approval of IDVYNSO for HIV and the introduction of NUMELVI in animal health, as essential to this quarter’s performance.

Looking ahead, Merck’s updated guidance reflects optimism around new product launches and a diversified late-stage pipeline, supported by ongoing investments in research and commercial capabilities. CEO Robert Davis said, “We’re in the midst of initial launches of over 20 new products, almost all of which have blockbuster potential across a broad set of therapeutic areas.” Management signaled upcoming Phase III data readouts, regulatory milestones, and a portfolio transformation that is expected to expand Merck’s commercial opportunities through the next decade.

Key Insights from Management’s Remarks

Management cited strong oncology performance, new launches, and pipeline progress as central to the quarter, while recent organizational changes and business development activity are designed to position Merck for long-term growth.

• Oncology momentum: KEYTRUDA and WELIREG saw increased demand, driven by uptake in metastatic and earlier-stage cancers and new international launches. Management highlighted positive feedback on the KEYTRUDA QLEX launch and noted WELIREG’s expanding use in renal cell carcinoma.
• New product launches: The company introduced IDVYNSO for HIV-1 in adults and NUMELVI, a second-generation JAK inhibitor for canine allergic dermatitis. These launches signal Merck’s commitment to expanding its reach beyond established franchises.
• Business development discipline: The planned acquisition of Terns Pharmaceuticals was highlighted for its potential to add a best-in-class therapy (TERN-701) for chronic myeloid leukemia, with management noting, “We believe TERN-701 has multibillion-dollar commercial potential and will be a significant driver of growth in the next decade.”
• Operating structure evolution: Merck reorganized its commercial operations into new business units focused on specific therapeutic areas, aiming to sharpen execution and agility. Experienced leaders were appointed to head specialty pharma, infectious diseases, and oncology units.
• Artificial intelligence initiatives: The company announced a multi-year partnership with Google Cloud and expanded collaborations with Tempus AI and the Mayo Clinic, aiming to enhance productivity, accelerate drug discovery, and improve the odds of pipeline success.

Drivers of Future Performance

Merck’s outlook is underpinned by a diversified product portfolio, upcoming regulatory milestones, and continued investment in pipeline innovation and commercial expansion.

• Pipeline readouts and launches: Management expects multiple Phase III data readouts and regulatory decisions in oncology, cardiometabolic, and ophthalmology over the next 18 months. The anticipated launches of more than 20 products with blockbuster potential are expected to broaden revenue streams and reduce reliance on legacy brands.
• Business development and portfolio transformation: The integration of new assets like TERN-701, along with ongoing external partnerships, reflects a commitment to supplementing internal R&D with targeted acquisitions. Management stated that business development remains a strategic priority, particularly in oncology, immunology, and cardiometabolic diseases.
• Operational investments and expenses: Merck plans to increase commercial and R&D spending to support new launches and expand its pipeline. Management cautioned that near-term operating expenses will rise due to these investments, but they expect long-term value creation from expanded product reach and improved execution.

Catalysts in Upcoming Quarters

Looking forward, our analysts will be monitoring (1) the pace and uptake of new product launches, especially in oncology and specialty medicines, (2) progress toward key regulatory approvals and Phase III readouts for late-stage pipeline assets, and (3) the integration and performance of recently acquired or partnered assets such as TERN-701. Execution on commercial expansion and the impact of AI partnerships will also be key areas of focus.

Merck currently trades at $111.25, in line with $111.02 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.